M28 Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

M28 Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-55,200	Closed	-$2.44M	–	11
2025 Q1	$2.44M	Sell	55,200 -55,200	-50%	-$2.54M	3.34%	6
2024 Q4	$3.99M	Hold	110,400	–	–	3.92%	5
2024 Q3	$3.54M	Hold	110,400	–	–	3.89%	6
2024 Q2	$4.16M	Hold	110,400	–	–	5.39%	5
2024 Q1	$5.43M	Sell	110,400 -32,400	-23%	-$1.5M	4.02%	6
2023 Q4	$5.21M	Sell	142,800 -54,900	-28%	-$1.43M	4.32%	6
2023 Q3	$4.57M	Hold	197,700	–	–	5.24%	4
2023 Q2	$5.18M	Hold	197,700	–	–	6.85%	4
2023 Q1	$5.09M	Buy	197,700 +87,800	+80%	+$2.57M	5.75%	5
2022 Q4	$2.86M	Buy	+109,900	New	+$2.71M	2.72%	9

Other funds holding SWTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

M28 Capital Management's SWTX Position: Q2 2025 in Review

M28 Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 55,200 shares — an estimated $2.44M sold.

M28 Capital Management first reported a position in SWTX in Q4 2022 and held it in 10 quarters. The position peaked at $5.43M in Q1 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

M28 Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
M28 Capital Management sold 55,200 SpringWorks Therapeutics shares in Q2 2025, an estimated $2.44M.
M28 Capital Management first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 10 quarters.
M28 Capital Management's SpringWorks Therapeutics position peaked at $5.43M in Q1 2024.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on M28 Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.